21
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A novel nomogram for predicting liver metastasis in patients with gastrointestinal stromal tumor: a SEER-based study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Liver metastasis (LIM) of gastrointestinal stromal tumor (GIST) is associated with poor prognosis. The present study aimed at developing and validating nomogram to predict LIM in patients with GIST, thus helping clinical diagnosis and treatment.

          Methods

          The data of GIST patients derived from Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2016, which were then screened by univariate and multivariate logistic regression for the construction of LIM nomogram. The model discrimination of LIM nomogram was evaluated by concordance index (C-index) and calibration plots, while the predictive accuracy and clinical values were measured by decision curve analysis (DCA) and clinical impact plot. Furthermore, we validated predictive nomogram in the internal testing set.

          Results

          A total of 3797 patients were enrolled and divided randomly into training and validating groups in a 3-to-1 ratio. After logistic regression, the significant variables were sex, tumor location, tumor size, N stage and mitotic rate. The calibration curves showed the perfect agreement between nomogram predictions and actual observations, while the DCA and clinical impact plot showed the clinical utility of LIM nomogram. C-index of the nomogram was 0.812. What’s more, receiver operating characteristic curves (ROC) also showed good discrimination and calibration in the training set (AUC = 0.794, 95% CI 0.778–0.808) and the testing set (AUC = 0.775, 95% CI 0.748–0.802).

          Conclusion

          The nomogram for patients with GIST can effectively predict the individualized risk of liver metastasis and provide insightful information to clinicians to optimize therapeutic regimens.

          Related collections

          Most cited references61

          • Record: found
          • Abstract: found
          • Article: not found

          PDGFRA activating mutations in gastrointestinal stromal tumors.

          Most gastrointestinal stromal tumors (GISTs) have activating mutations in the KIT receptor tyrosine kinase, and most patients with GISTs respond well to Gleevec, which inhibits KIT kinase activity. Here we show that approximately 35% (14 of 40) of GISTs lacking KIT mutations have intragenic activation mutations in the related receptor tyrosine kinase, platelet-derived growth factor receptor alpha (PDGFRA). Tumors expressing KIT or PDGFRA oncoproteins were indistinguishable with respect to activation of downstream signaling intermediates and cytogenetic changes associated with tumor progression. Thus, KIT and PDGFRA mutations appear to be alternative and mutually exclusive oncogenic mechanisms in GISTs.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators

            Context: Urologists regularly develop clinical risk prediction models to support clinical decisions. In contrast to traditional performance measures, decision curve analysis (DCA) can assess the utility of models for decision making. DCA plots net benefit (NB) at a range of clinically reasonable risk thresholds. Objective: To provide recommendations on interpreting and reporting DCA when evaluating prediction models. Evidence acquisition: We informally reviewed the urological literature to determine investigators’ understanding of DCA. To illustrate, we use data from 3616 patients to develop risk models for high-grade prostate cancer ( n = 313, 9%) to decide who should undergo a biopsy. The baseline model includes prostate-specific antigen and digital rectal examination; the extended model adds two predictors based on transrectal ultrasound (TRUS). Evidence synthesis: We explain risk thresholds, NB, default strategies (treat all, treat no one), and test tradeoff. To use DCA, first determine whether a model is superior to all other strategies across the range of reasonable risk thresholds. If so, that model appears to improve decisions irrespective of threshold. Second, consider if there are important extra costs to using the model. If so, obtain the test tradeoff to check whether the increase in NB versus the best other strategy is worth the additional cost. In our case study, addition of TRUS improved NB by 0.0114, equivalent to 1.1 more detected high-grade prostate cancers per 100 patients. Hence, adding TRUS would be worthwhile if we accept subjecting 88 patients to TRUS to find one additional high-grade prostate cancer or, alternatively, subjecting 10 patients to TRUS to avoid one unnecessary biopsy. Conclusions: The proposed guidelines can help researchers understand DCA and improve application and reporting. Patient summary: Decision curve analysis can identify risk models that can help us make better clinical decisions. We illustrate appropriate reporting and interpretation of decision curve analysis.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden.

              Recent breakthroughs regarding gastrointestinal stromal tumors (GIST) and their pathogenesis have redefined diagnostic criteria and have led to the development of molecularly targeted drug therapy. New treatment options mandate more accurate information regarding the incidence, prevalence, clinical behavior, and prognostic factors of GIST. All patients (n=1460) who potentially had GIST diagnosed from 1983 to 2000 in western Sweden (population, 1.3-1.6 million) were reviewed, and 288 patients with primary GIST were identified. The incidence and prevalence of GIST were determined, and predictive prognostic factors, including current risk-group stratifications, were analyzed statistically. Ninety percent of GISTs were detected clinically due to symptoms (69%) or were incidental findings at surgery (21%); the remaining 10% of GISTs were found at autopsy. Forty-four percent of symptomatic, clinically detected GISTs were categorized as high risk (29%) or overtly malignant (15%), with tumor-related deaths occurring in 63% of patients and 83% of patients, respectively (estimated median survival, of 40 months and 16 months, respectively). Tumor-related deaths occurred in only 2 of 170 of patients (1.2%) with very-low-risk, low-risk, or intermediate-risk tumors. The annual incidence of GIST was 14.5 per million. The prevalence of all GIST risk groups was 129 per million (31 per million for the high-risk group and the overtly malignant group). GIST has been under recognized: Its incidence, prevalence, and clinical aggressiveness also have been underestimated. Currently existing risk-group stratification systems based on tumor size and mitotic rate delineate GIST patients who have a poor prognosis. Prognostication in patients with GIST can be refined using a proposed risk score based solely on tumor size and proliferative index. Copyright (c) 2005 American Cancer Society.
                Bookmark

                Author and article information

                Contributors
                love_ggw2@163.com
                doctormachaoqun@gmail.com
                Journal
                BMC Surg
                BMC Surg
                BMC Surgery
                BioMed Central (London )
                1471-2482
                25 November 2020
                25 November 2020
                2020
                : 20
                : 298
                Affiliations
                [1 ]GRID grid.410745.3, ISNI 0000 0004 1765 1045, Department of General Surgery, Jiangsu Province Hospital of Chinese Medicine, , Affiliated Hospital of Nanjing University of Chinese Medicine, ; Nanjing, 210029 Jiangsu Province China
                [2 ]GRID grid.440320.1, ISNI 0000 0004 1758 0902, Department of General Surgery, , Xinyang Central Hospital, ; Xin Yang, 464000 Henan Province China
                [3 ]GRID grid.410745.3, ISNI 0000 0004 1765 1045, Department of Pediatrics, Jiangsu Province Hospital of Chinese Medicine, , Affiliated Hospital of Nanjing University of Chinese Medicine, ; Nanjing, 210029 Jiangsu Province China
                [4 ]GRID grid.410745.3, ISNI 0000 0004 1765 1045, Department of Gynecology, Jiangsu Province Hospital of Chinese Medicine, , Affiliated Hospital of Nanjing University of Chinese Medicine, ; Nanjing, 210029 Jiangsu Province China
                Author information
                http://orcid.org/0000-0002-0201-8218
                Article
                969
                10.1186/s12893-020-00969-4
                7689971
                33238982
                cfe57a1a-56b4-44e6-b0c8-f35e4ca1991c
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 2 August 2020
                : 17 November 2020
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100001809, National Natural Science Foundation of China;
                Award ID: 8170151341
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100005145, Basic Research Program of Jiangsu Province;
                Award ID: BK20161086
                Award ID: BK20181506
                Award Recipient :
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2020

                Surgery
                gastrointestinal stromal tumors,liver metastasis,nomogram,seer
                Surgery
                gastrointestinal stromal tumors, liver metastasis, nomogram, seer

                Comments

                Comment on this article